Joseph Obadiah is a Dermatology physician affiliated with Providence Health & Services. OpenAlex indexes 13 publications with 343 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5330 NE Glisan St
Suite 200
Portland, OR 972133069
Telephone
503-215-9080Provider last certified this registry record 22 Mar 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20231 payment
- PFIZER INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
28.7%Corticosteroid27.5%Hydrocortisone42%Clobetasol Propionate39%Betamethasone Diprop Augmented10%Desonide5%Hydrocortisone Butyrate4%Part D<11 patientsSulfonamide Antibacterial1.2%Sulfacetamide Sodium100%Part D≥12 patientsAnti-infectives
26.8%Azole Antifungal11%Ketoconazole76%Fluconazole24%Part D≥66 patientsTetracycline-class Drug6.3%Doxycycline Monohydrate100%Part D≥21 patients+ 4 more classes in this area
Dermatology
15.8%Corticosteroid7.4%Triamcinolone Acetonide100%Part D≥59 patientsInterleukin-4 Receptor alpha Antagonist5.7%Dupixent Pen77%Dupixent Syringe23%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- <i>Rickettsia honei</i> Infection in a Traveler Returning From India
Open Forum Infectious Diseases
2020 - Keloid formation occurring in the distribution of a congenital vascular malformation.
PubMed
2011 - Pemphigoid gestationis: cutaneous manifestation of impaired fetal allograft tolerance.
PubMed
2010 - Cutaneous Rosai-Dorfman Disease: Comprehensive Review of Cases Reported in the Medical Literature since 1990 and Presentation of an Illustrative Case
Journal of Cutaneous Medicine and Surgery
2006 - Severe insulin resistance associated with subcutaneous amyloid deposition
Diabetes Research and Clinical Practice
2006
Similar KOLs
Other experts from the same institution or the same specialty.
Melinda Burnett, MD
Providence Health & Services
John Zurasky, MD
Providence Health & Services
Alison Christy, MD, PhD
Providence Health & Services
Evthokia Hobbs, MD
Providence Health & Services
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”